Clinical trials added $763 million to New Zealand's economy in 2025, but that this is at risk as other countries become more competitive, according to a new report from NZIER, commissioned by Medicines New Zealand.
Clinical trials add hundreds of millions to the economy and support approximately 5,000 jobs, including 1,500 skilled roles in the health sector. For patients, trials offer earlier access to innovative treatments and care. For the country, trials bring in foreign investment through commercial trials backed by global sponsors.
“New Zealand has earned a positive reputation as a place for undertaking clinical trials, but reputation alone won’t keep sponsors coming. Other countries are actively competing to attract companies to run their clinical trials, and New Zealand needs to keep pace,” said Dr Graeme Jarvis, CEO of Medicines New Zealand.
The report highlighted that despite the growth potential, the sector is fragmented, and gets limited government promotion or investment, while countries such as Australia are actively improving their incentives, infrastructure and international promotion to attract trials.
New Zealand’s well-known poor OECD ranking for publicly funding modern medicines weakens New Zealand’s attractiveness as a place to conduct trials. This is because pharmaceutical companies are increasingly needing to pay for baseline standard-of-care medicines for New Zealand patients involved in trials so that a comparison with the new medicine being developed is possible.
In other countries these standard-of-care modern medicines are publicly funded, putting New Zealand at a cost disadvantage in a competitive market. Adding to this disadvantage, the trial sponsors may have to fund ongoing access to the study medicine for a lengthy indefinite period after the trial finishes because our medicines funding wait list can take years.
The report identifies several ways New Zealand could protect and grow its clinical trials sector. These range from recognising trials as a source of foreign investment and employment and providing better R&D incentives and international promotion, to generating a national coordination function that brings the public and private clinical trials sectors together. Well-resourced regulatory and ethical approval processes would also help protect New Zealand’s reputation for fast clinical trials approvals, and improving publicly funded access to existing modern medicines would also remove a growing barrier for New Zealand being a country of choice for company sponsors considering where to run their future clinical trials.
“New Zealand has what it takes to be a destination of choice for clinical trials. But the risk is that we will continue to lose ground to other countries without noticing, and by the time we act, the investment has already gone elsewhere,” said Dr Jarvis.
The economic contribution of clinical trials in New Zealand in 2025 is available here
END
Medicines New Zealand is the industry group representing biopharmaceutical companies operating in New Zealand. We advocate for the benefits of modern medicines and vaccines as part of a high-quality public health system.
Contact:
Grace Abbott, Digital Communications Advisor, Medicines New Zealand.
Ph: 027 534 6461